Novo led a $60m series B round for achondroplasia drug developer Therachon that also featured Pfizer Ventures.

Novo led a $60m series B round yesterday for Therachon, a Switzerland-based developer of treatments for rare genetic conditions, that included fellow pharmaceutical firm Pfizer’s corporate venturing unit, Pfizer Ventures. The round also featured Inserm Transfert Initiative, the investment arm of research institute Inserm, as well as Bpifrance, Cowen Healthcare Investments, Versant Ventures, OrbiMed and funds…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.